Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Failed drug program
Biotech
BioMarin axes $270M asset after missing phase 3 endpoint
BioMarin Pharmaceutical has ended development of BMN 401 across all indications, months after reporting mixed phase 3 data on the rare-disease prospect.
Nick Paul Taylor
Aug 7, 2026 9:10am
Ignota buys Kronos' pipeline to rescue shelved programs
Oct 6, 2025 5:45am
PepGen ends all DMD work after phase 2 trial falls flat
May 28, 2025 5:30pm
Lundbeck slashes value of $250M Abide buyout after pain setback
Oct 24, 2024 7:20am
Eliem shuts down final drug program 5 months after major layoffs
Jul 20, 2023 9:05am
Novartis axes obesity drug as high-risk, high-reward bet fails
Jul 18, 2023 5:47am
